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Amiodarone can cause serious lung toxicity (1). Our
experience suggests differences in clinical practice between
hospitals and between consultants in the monitoring and
management of lung problems due to amiodarone. A recent
editorial (2) highlighted the potential pulmonary risks of
amiodarone but gave no recommendations on the monitor-
ing of lung function. We set out to assess the practice of the
respiratory and cardiology consultants in the Trent region.
Methods
A questionnaire on clinician’s usual practice for monitoring
the lungs at the start of and during, amiodarone therapy
was sent to cardiology and respiratory consultants in the
Trent region. Questions were asked about the management
of abnormal pulmonary function tests (PFTs) in sympto-
matic and asymptomatic patients and on the number of
adverse pulmonary effects encountered in the preceding 12
months.
Results
Of the 61 consultants mailed [cardiology (C) n=27;
respiratory (R) n=34], 49 replied (C: n=21 77%; R:
n=28 82%). The response to requests for PFTs prior to
starting treatment and the tests requested and the PFT
requests after the initiation of amiodarone are set out in
Table 1. One respiratory physician had no policy for testing
PFTs and another never used amiodarone. There was a
significant difference between cardiologists and respiratory
physicians in the request of baseline PFTs (P50?01).
Fifteen percent of consultants routinely repeat PFTs on all
patients after intervals varying between 3 and 12 months
(C: n=2, 10%; R: n=5, 19%).
In a hypothetical patient with no pulmonary symptoms
but a fall of 20% in transfer factor (TLCO), 39% would
continue amiodarone (C: n=7, 50%; R: n=8, 33%) andReceived 16 May 2000 and accepted 16 May 2000.
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on the clinical necessity for the drug.
In the previous year 10 consultants had stopped
amiodarone due to presumed pulmonary toxicity (C:
n=4; R: n=6), the most important criteria being the chest
radiograph (five cases), clinical signs (four cases) and the
PFTs (one case). Forty-one percent of consultants would
never discharge a patient taking long-term amiodarone
from hospital follow-up (C: n=8, 38%; R: n=11, 44%)
whereas 59% accept general practitioner follow-up.
Discussion
This survey confirms wide variations in the management of
patients prescribed amiodarone with regards to lung effects.
Two thirds of consultants routinely check baseline PFTs in
all or some patients and of these one quarter repeat tests
routinely or in those perceived to be at risk of developing
lung side-effects (3,4). Some consultants request PFTs only
if there are changes in symptoms and some do not request
PFTs at all.
Amiodarone lung toxicity is observed in up to 5% of
patients on long-term treatment (5). Symptoms may include
an insidious increase in shorteness of breath, a non-
productive cough, fever, weight loss and pleurisy. It may
be dicult to distinguish lung toxicity from pulmonary
oedema when there is underlying left ventricular impair-
ment. The diagnosis of amiodarone lung is made with two
or more of the following; new or worsening symptoms;
chest radiograph changes; a fall in TLCO or total lung
capacity of 15% or more (6). Pulmonary toxicity appears to
be related both to the mean daily and cumulative dose of
amiodarone (7) although it can occur with only 200mg per
day (8–10). On withdrawal of amiodarone there is usually
resolution but occasionally symptoms are progressive and
treatment with steroids remains controversial (11).
This study revealed differences between and within
specialities. Prospective studies suggest baseline tests that
include TLCO may highlight patients who are at increased
risk for developing problems (3,4,12). Respiratory physi-
cians are more likely than cardiologists to test all patients
routinely, possibly to acquire a baseline. Cardiologists are
more likely to perform baseline PFTs on those with
underlying lung disease and therefore perceived increased
risk. A quarter of consultants who request baseline tests ask# 2000 HARCOURT PUBLISHERS LTD
TABLE 1. Response to questions on pulmonary function testing for patients prescribed amiodarone
Respiratory [% (n)] Cardiology [% (n)]
‘When would you ask for pulmonary function tests before starting amiodarone?’
Routinely in all patients 41 (11) 14 (3)
Underlying lung disease only 15 (4) 57 (12)
Never 41 (11) 29 (6)
Other 3 (1) 0 (0)
‘Which pulmonary function tests do you request before starting amiodarone?’
Spirometry alone 19 (3) 7 (1)
Lung volumes & TLCO 69 (11) 87 (13)
Arterial blood gases (in addition) 12 (2) 7 (1)
‘When would you carry out follow-up pulmonary function tests?
Routinely 19 (5) 10 (2)
Low baseline TLCO 8 (2) 10 (2)
Change in symptoms 54 (14) 67 (14)
Never 19 (5) 14 (3)
AMIODARONE AND THE LUNG 1131for spirometry alone, which is inadequate for assessing
patients at increased risk, or request arterial blood gases,
which are invasive and unhelpful.
There was a difference in the action that would be taken
in response to an asymptomatic fall of 20% in TLCO.
Several studies cite falls of 20% in TLCO which stabilize or
improve despite the amiodarone being continued and with
none developing overt pulmonary toxicity (12,13). In those
who routinely monitor PFTs, action taken on a lone fall in
TLCO with no deterioration in symptoms or radiographi-
cal change, may lead to the stopping of an effective
antiarrhythmic agent. There also appears to be no warning
of the onset of toxicity with serial measurement (12) and
this suggests that routinely repeating PFTs in asympto-
matic patients is unfruitful.
More respiratory consultants had stopped amiodarone
due to pulmonary toxicity in the previous 12 months. This
may due to chance, a greater awareness of the respiratory
cause for symptoms or that they are more likely to be
referred patients who develop shortness of breath. Patients
under the care of respiratory consultants may also have a
lesser clinical necessity for the drug, for example non-life
threatening arrhythmias.
In conclusion, the results confirm wide variations between
consultants in the monitoring of pulmonary function in
patients prescribed amiodarone. These variations may be
important in patient care and have financial and medicolegal
implications. There is need for a consensus view on this issue.
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